Delivery Order SPE2DB24D1021-SPE2DB25FEZLY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units valued at $1,594.16. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and no set-aside designation was applied. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 ml auto-injector vials with a ceiling value of $1,594.16. This delivery order, issued on June 20, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This award represents a continuation of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units with a firm fixed price ceiling value of $1,594.16 and an ultimate completion date of August 26, 2025. This non-set-aside award operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials with a firm fixed price ceiling value of $3,188.32. This is a competitively awarded, non-set-aside delivery order with an ultimate completion date of August 26, 2025. AmerisourceBergen Drug Corp will perform the work at its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a $28,694.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 ml auto-injectors. This non-set-aside contract, issued on July 31, 2025, requires completion by August 21, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,753.28 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL auto-injectors. This firm fixed-price, non-set-aside contract is scheduled for completion by August 8, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL auto-injector units, with a contract ceiling value of $1,594.16 and an ultimate completion date of August 22, 2025. This firm fixed-price delivery order, awarded on August 1, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials with a firm fixed price ceiling value of $3,188.32 and an ultimate completion date of August 26, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $15,941.60 on July 23, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp will perform this contract from its corporate office location in Conshohocken, Pennsylvania, the company's headquarters. The delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $3,188.32. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZLYDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,188.32 on August 8, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded procurement under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its comprehensive IDC with the DLA. The parent contract enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. This delivery order exemplifies the company's role in fulfilling specialized pharmaceutical needs for the Defense Health Agency and other government healthcare systems through the flexible Pharmaceutical Prime Vendor Global Program framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/8/25 |